Key Takeaways
- ARV collapse drives a reset quarter: Tenofovir contribution crashed from ~42% of revenue in Q1 FY22 to barely 2% in Q1 FY23 as government tenders dried up, forcing the company to accelerate a diversification it had already begun.
- Ibuprofen is the bridge to FY24: The recently commercialized product is expected to contribute 35–40% of the top line in FY24, with a full-fledged commercial launch targeted by Q4 FY23 once customer qualifications and regulatory processes conclude.
- JV portfolio begins to fire: Sitagliptin, Vildagliptin, and perampanel all launched commercially in the last one to two months, with the JV expected to contribute 15–25% of revenue going forward.
- Turnaround promised on a tight clock: Management targets EBITDA-positive by end of Q2 FY23 and PAT-positive by end of FY23, pinning the recovery on Ibuprofen ramp, JV launches, and an industry bounce-back it expects in the next couple of quarters.
- What to watch next quarter: Whether the Ibuprofen customer qualification timeline holds, any clarity on ARV tender forecasting from partners, and whether the Q2 EBITDA-positive target is met.
The ARV Cliff & Diversification
- Tenofovir tender collapse: Government tender focus shifted entirely to COVID-related injections, vaccines, and medication, diverting funds away from antiretroviral procurement and causing significant delays; Tenofovir contribution fell from ~42% in Q1 FY22 to hardly 2% in Q1 FY23.
- Forecasting remains blind: Management is trying to push partners for projections but concedes it is very difficult to predict until it knows who won the tender; some clarity may emerge by next quarter.
- Diversification was already underway: The company had been working to decentralize revenue away from the single-product concentration, with Ibuprofen, JV products, and new R&D candidates forming the replacement base.
- Molnu raw material stranded: Raw material purchased for Molnu cannot currently be used for other ARV products, but management will liquidate the inventory if an opportunity arises where the same raw material is used in another product.
Vamsi Krishna Potluri: "That particular product's contribution is around 42% in the last Q1 FY22 actually. Q1 FY22, that was around 42% was the contribution of that particular product. So, we want to, you know, more... decentralize our revenue, and we want to go in a different direction."
Ibuprofen: The FY24 Anchor
- Commercial ramp timeline: Full-fledged commercial launch expected by end of this year (Q4 FY23); customer qualification and post-approval submission with the agency takes approximately six months, and initial traction is already strong.
- FY24 revenue contribution: Management expects Ibuprofen to contribute 35–40% of the top line in FY24, per an internal calculation shared on the call.
- Growth ambition: Targeting 30–35% growth going forward, supported by new customer addition and geographical expansion.
- European entry unlocked: CEP approval received in the last week of July enables sales in European markets and qualification by customers worldwide; the company is aggressively marketing in Europe and other RoW countries.
- Capacity utilization on track: Expecting to exit Q4 FY23 at a 70–80% run rate, consistent with prior guidance.
- Pricing bottomed out: Prices have returned to pre-2017-18 levels below $10/kg; management believes prices have bottomed and will probably not go down further, and engineered the product and process specifically to compete at this range.
Vamsi Krishna Potluri: "We have developed the product and process and our engineering has been done in such a way that we will be competing in the market. So, as of now there is, I mean, obviously, there is price pressure, obviously, higher price. All of us are happy. But still we are with the current price also we will be able to compete in the market."
JV Portfolio: Launches Converting to Revenue
- Four products now commercial: Sitagliptin launched one month ago, Vildagliptin launched just last month, perampanel launched in the domestic market, and Ranolazine has been commercial for one year.
- Sitagliptin is the headline: The ₹100 crore sales target (20% market share of a ₹500 crore market) remains intact and could grow a little higher; FY23 sales are expected at ₹70–80 crore, with supplies to the JV partner already started and the product out in the market post patent expiry.
- JV revenue contribution: Expected to reach around 15% of the top line, possibly 20–25% due to the Sitagliptin launch.
- Pipeline depth: Eight products are part of the JV; all except one or two have been validated, with commercialization waiting on patent expiry.
- Domestic cost play: The company is working on a different route of synthesis for Sitagliptin in the Indian market to be cost-competitive.
VKT: Early-Stage ANDA Play
- First ANDA commercialized: VKT received ANDA approval in March; commercial launches began in May and June with front-end partners, generating ₹9.86 crore in revenue but a loss of ₹7.02 crore in the June quarter as initial expenses were booked.
- Pipeline build-out: Two more ANDAs are in the filing stage and expected to be filed by end of FY23; these are filings, not approvals.
- Ranitidine on hold: VKT's ranitidine ANDAs remain on hold by the agency; discussions are ongoing but management stated "as of now there is no update. It's at a standstill right now."
Industry Context & Margin Dynamics
- Post-COVID inventory overhang: The industry is sitting on stocks because product movement in the market is low post-COVID; companies are reducing prices and sacrificing margins to move inventory, a dynamic management expects to be temporary.
- SMS inventory build explained: The major inventory increase from Q4 FY22 to Q1 FY23 was driven by the Sitagliptin launch; earlier inventory build in Q4 FY22 reflected raw material positioning for a major product going off patent, plus orders for commodity products like Ibuprofen and triptans.
- Raw material posture: The company holds ₹125 crore in raw material, sufficient for the next two months, and is not purchasing major raw material in the current quarter.
- ARV pricing stable: Tenofovir pricing has not depreciated too much, maybe 5% here and there; SMS operates as a CMO where customers provide raw material, so raw material price is immaterial to its economics.
Vamsi Krishna Potluri: "The industry is sitting on stocks. So, if you see the stock inventory level of almost all the major companies, you see the inventory level, even including our company, has grown decently. The reason is because the movement of a product in the market is less. So, in order to compensate the movement, I think, you know, people are going down on the price, and they are sacrificing the margins in order to move the product that is sitting in the inventory."
R&D & New Product Strategy
- Shift toward new products: R&D focus is moving from cost-effective processes for old products (Ibuprofen, Famotidine, sildenafil, Tadalafil) toward the new product segment, with a few more products recently added.
- Tactical launches planned: The company will launch tactical products as per need and market demand to deepen customer engagement and provide operating leverage.
- Pipeline visibility limited: Management is working on cost-effective processes for 2–3 more products, described as regular products where SMS can add value based on manufacturing strengths, expected to reflect in the product list in H2; no specific product names were disclosed when asked.
- Anti-diabetic opportunity: Planning to launch a recently expired patent of an anti-diabetic product.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA turnaround | Turn EBITDA positive | By end of Q2 FY23 |
| PAT turnaround | Turn PAT positive | By end of FY23 |
| Ibuprofen full commercial launch | Full-fledged commercial launch post customer qualification and PAS | By Q4 FY23 |
| Ibuprofen capacity utilization | Exit at 70–80% run rate | By Q4 FY23 |
| Ibuprofen FY24 revenue contribution | 35–40% of top line | FY24 |
| VKT ANDA filings | File two more ANDAs (filings, not approvals) | By end of FY23 |
| Sitagliptin FY23 sales | ₹70–80 crore | FY23 |
| ARV tender clarity | Some clarity from partners on forecasting | Possibly by next quarter |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹9.86 cr (VKT only), sequential improvement with turnaround at EBITDA level |
| EBITDA | Turnaround at EBITDA level on sequential basis |
| VKT net loss | ₹7.02 cr |
| R&D expense | ~4% of revenue in FY22, planned growth of ~20% in FY23 |
| Tenofovir revenue contribution | Hardly 2%, down from 42% in Q1 FY22 |
| Anti-migraine revenue contribution | Roughly 30% |
| Ibuprofen revenue contribution | Less than 10% |
| Ibuprofen capacity utilization | 22% |
| Ibuprofen current price | Less than $10 per kilo, management believes prices have bottomed out |
| JV revenue contribution (current FY) | About 11% |
| JV revenue contribution (expected) | 15% to 25% of top line going forward |
| SMS stake in JV | 45% |
| Total inventory | ₹275 cr approximately |
| WIP and finished goods inventory | ₹150 cr |
| Raw materials inventory | ₹125 cr |
| Sitagliptin capacity | 10 to 15 metric tons per month |
| Sitagliptin FY23 sales target | ₹70–80 cr (per an analyst's math) |
| Sitagliptin market share target | At least 20% of ₹500 cr market (per an analyst's math) |
| VKT ANDAs | 6 currently, 2 more to be filed in FY23 |
| Non-ARV commercial launches in FY22 | 3 products |
| Typical annual price erosion (old products) | 5% to 8% |
| Ibuprofen Q4 FY23 capacity utilization target | 70% to 80% run rate |
| Ibuprofen FY24 revenue contribution target | 35% to 40% of top line |